argenx to Present at Goldman Sachs 45th Annual Global Healthcare Conference
argenx, a global immunology company focused on severe autoimmune diseases, will participate in the Goldman Sachs 45th Annual Global Healthcare Conference on June 11, 2024, at 2:40 PM ET in Miami, FL. Management will engage in a fireside chat. The live webcast can be accessed via the argenx website, with a replay available for 90 days post-event.
- Participation in a prestigious event such as the Goldman Sachs 45th Annual Global Healthcare Conference can enhance visibility and credibility for argenx.
- Opportunities for investor engagement and potentially attracting new investments.
- No immediate financial or clinical data updates were provided in the announcement, which might be expected by investors.
- The announcement lacks concrete details on how this participation will directly impact the company's business outcomes or stock performance.
June 4, 2024
Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of management will participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference on Tuesday, June 11, 2024 at 2:40 PM ET in Miami, FL.
A live webcast of the fireside chat may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be available on the argenx website for approximately 90 days following the fireside chat.
About argenx
argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker, globally in the U.S., Japan, Israel, the EU, the UK, China and Canada. The Company is evaluating efgartigimod in multiple serious autoimmune diseases and advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit www.argenx.com and follow us on LinkedIn, X/Twitter, Instagram, Facebook, and YouTube.
For further information, please contact:
Media:
Ben Petok
bpetok@argenx.com
Investors:
Alexandra Roy (US)
aroy@argenx.com
Lynn Elton (EU)
lelton@argenx.com
FAQ
When will argenx participate in the Goldman Sachs 45th Annual Global Healthcare Conference?
Where can I watch the argenx fireside chat at the Goldman Sachs Healthcare Conference?
How long will the replay of the argenx fireside chat be available?
